Filtered By:
Source: Applied Health Economics and Health Policy
Condition: Bleeding
Management: Economics
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective
ConclusionCompared to aspirin, apixaban is likely to be cost effective in preventing thromboembolic disease among VKA unsuitable patients with atrial fibrillation.
Source: Applied Health Economics and Health Policy - October 3, 2016 Category: Health Management Source Type: research
